One of the main findings of this meta-analysis was that high FGF21 levels were independently and significantly associated with an increased long-term risk of MACE in patients with CAD (multivariate HR: 1.77, 95% CI: 1.40–2.23, P < 0.05, I2 = 0%, fixed-effect model). Here, FGF21 is linked to coronary artery disorder.